CAS 868049-49-4|Olodaterol
Introduction：Basic information about CAS 868049-49-4|Olodaterol, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Olodaterol | ||
|---|---|---|---|
| CAS Number | 868049-49-4 | Molecular Weight | 386.441 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 649.0±55.0 °C at 760 mmHg |
| Molecular Formula | C21H26N2O5 | Melting Point | / |
| MSDS | / | Flash Point | 346.3±31.5 °C |
Names
| Name | olodaterol |
|---|---|
| Synonym | More Synonyms |
Olodaterol BiologicalActivity
| Description | Olodaterol (BI1744) is a selective, long acting β2-adrenoceptor (β2-AR) agonist (EC50=0.1 nM and pKi= 9.14 for human β2-adrenoceptor, respectively). Olodaterol can be used for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis[1][2][3]. |
|---|---|
| Related Catalog | Research Areas >>EndocrinologySignaling Pathways >>GPCR/G Protein >>Adrenergic ReceptorResearch Areas >>Inflammation/Immunology |
| Target | β2 adrenoceptor:0.1 nM (EC50) |
| In Vitro | Olodaterol (0.001~10 nM; fibroblasts) attenuates growth factor-induced motility and proliferation[2]. Olodaterol (0.1~10 nM; fibroblasts) interferes with FGF-induced phosphorylation of signalling cascades[2]. Olodaterol (0.001~1000 nM; 30 minutes; fibroblasts) increases intracellular cAMP in a concentration-dependent manner. Olodaterol (0~10 nM; 30 minutes; fibroblasts) concentration-dependently inhibits the PICP increase with maximal efficacy of 70 % at 10 nM. Olodaterol has a subnanomolar affinity for the β2-AR (pKi=9.14) and is selective for this receptorin comparison with the β1-AR and β3-AR subtypes[2]. Western Blot Analysis[2] Cell Line: Fibroblasts Concentration: 0.1~10 nM Incubation Time: Result: Interfered with FGF-induced phosphorylation of signalling cascades. Cell Proliferation Assay[2] Cell Line: Fibroblasts Concentration: 0.001~10 nM Incubation Time: Result: Attenuated growth factor-induced motility and proliferation. |
| In Vivo | Olodaterol (1 mg/kg; inhal.; 21 days) accelerats body weight recovery back to control levels (at day 21) and attenuats TGF-β-induced lung fibrosis[2]. Olodaterol (0.1~3 μg/kg; inhal.; 5 hours) induces a dose-dependent bronchoprotection[3]. Olodaterol (0.3 and 0.6 μg/kg; inhal.; 24 hours) induces a maximal bronchoprotection of approximately 60 % after 0.5 hours[3]. Animal Model: Lung fibrosis C57BL/6 mice Dosage: 1 mg/mL Administration: Inhal.; 21 days Result: Accelerated body weight recovery back to control levels (at day 21) and attenuated TGF-β-induced lung fibrosis. Animal Model: Guinea Pigs Dosage: 0.1~3 μg/kg Administration: Inhal.; 5 hours Result: Induced a dose-dependent bronchoprotection. Animal Model: Dogs Dosage: 0.3 and 0.6 μg/kg Administration: Inhal.; 24 hours Result: Olodaterol (0.6 μg/kg) induced a maximal bronchoprotection of approximately 60 % after 0.5 hours. |
| References | [1]. Xing G, et al. Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β2-adrenoceptor agonists. Bioorg Med Chem. 2020;28(1):115178. [2]. Herrmann FE, et al. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. Br J Pharmacol. 2017;174(21):3848-3864. [3]. Bouyssou T, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models [published correction appears in J Pharmacol Exp Ther. 2013 Jul;346(1):161]. J Pharmacol Exp Ther. 2010;334(1):53-62. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 649.0±55.0 °C at 760 mmHg |
| Molecular Formula | C21H26N2O5 |
| Molecular Weight | 386.441 |
| Flash Point | 346.3±31.5 °C |
| Exact Mass | 386.184174 |
| PSA | 103.54000 |
| LogP | 1.17 |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.596 |
| InChIKey | COUYJEVMBVSIHV-SFHVURJKSA-N |
| SMILES | COc1ccc(CC(C)(C)NCC(O)c2cc(O)cc3c2OCC(=O)N3)cc1 |
Synonyms
| 6-Hydroxy-8-[(1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methyl-2-propanyl]amino}ethyl]-2H-1,4-benzoxazin-3(4H)-one |
| Striverdi Respimat |
| BI 1744 |
| 6-hydroxy-8-[(1R)-1-hydroxy-2-[[1-(4-methoxyphenyl)-2-methylpropan-2-yl]amino]ethyl]-4H-1,4-benzoxazin-3-one |
| UNII-VD2YSN1AFD |
| 2H-1,4-Benzoxazin-3(4H)-one, 6-hydroxy-8-[(1R)-1-hydroxy-2-[[2-(4-methoxyphenyl)-1,1-dimethylethyl]amino]ethyl]- |
| Olodaterol |
